2-(2-氨基-3-(4-溴苯甲酰基)苯)乙酸, 98%|2-(2-Amino-3-(4-bromobenzoyl)phenyl)acetic acid|cas:91714-94-2|西域试剂

2-(2-氨基-3-(4-溴苯甲酰基)苯)乙酸, 98%,2-(2-Amino-3-(4-bromobenzoyl)phenyl)acetic acid

产品编号：西域试剂-WR182185| CAS NO：91714-94-2| MDL NO：MFCD00864341| 分子式：C₁₅H₁₂BrNO₃| 分子量：334.17

溴芬酸是一种有效的口服活性COX抑制剂，COX-1和COX-2的IC50分别为5.56和7.45 nM。溴芬酸可用于眼部炎症研究。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
西域试剂-WR182185		￥225.00	杭州北京（现货）
西域试剂-WR182185		￥614.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

英文名称	2-(2-Amino-3-(4-bromobenzoyl)phenyl)acetic acid
CAS编号	91714-94-2
产品描述	溴芬酸是一种有效的口服活性COX抑制剂，COX-1和COX-2的IC50分别为5.56和7.45 nM。溴芬酸可用于眼部炎症研究。
产品熔点	-129ºC
产品沸点	562.2±50.0 °C at 760 mmHg
产品密度	1.6±0.1 g/cm3
产品闪点	293.8±30.1 °C
精确质量	333.000061
PSA	80.39000
LogP	2.72
蒸气压	0.0±1.6 mmHg at 25°C
折射率	1.663
靶点	Human COX-1:5.56 nM (IC50) Human COX-2:7.45 nM (IC50)
体外研究	溴芬酸（0-80μg/mL；24小时）可以浓度依赖性方式抑制转化生长因子-β2诱导的HLEC-B3上皮-间充质转化。溴芬酸（80μg/Ml；48小时）抑制转化生长因子-β2诱导的人前囊上皮-间质转化。细胞存活率测定细胞系：转化生长因子-β2处理的人前囊浓度：80μg/mL孵育时间：48小时结果：抑制转化生长因子β2诱导的原代LEC上皮-间充质转化。细胞迁移试验细胞系：HLEC-B3细胞浓度：0、20、40、60和80μg/mL孵育时间：24小时结果：抑制转化生长因子-β2诱导的HLEC-B3细胞的细胞迁移，并抑制上皮-间质转化标记物的过度表达。
体内研究	溴芬酸（0.0032-3.16%；100或200μL；涂抹在背部）在大鼠体内产生显著的抗炎活性，浓度低至0.1%（4小时预处理时间）或0.32%（18小时预处理）。溴芬酸（0.032-3.16%；100μL；擦在爪子上）在大鼠体内产生剂量相关的抗炎活性。溴芬酸（0.032-1.0%；50μL）在直接应用于豚鼠暴露于紫外线的皮肤区域时，其阻断红斑的效力是消炎痛的26倍。溴芬酸（0.0032-0.1%；50μL；每天在未注射的爪子上摩擦4小时，每周5天）会导致大鼠两后肢爪子体积的剂量和时间依赖性减少。溴芬酸（0.32%；50μL；涂抹在腹部）对小鼠ACh攻击的腹部收缩产生显著的阻断作用。溴芬酸（滴眼液；每眼1μL（0.09%）；每天两次；4W）部分减少角膜染色，并在4周时间点变得更慢。动物模型：雄性Sprague-Dawley大鼠（150-250 g）注射卡拉胶剂量：0.0032、0.01、0.032、0-1、0.32、1.0、3.16%（100或200μL）给药：在注射卡拉胶1-72小时前擦到背部。结果：在卡拉胶激发前1、2和4小时以0.32%的浓度施用时，产生显著的抗炎活性。在卡拉胶激发前1或4小时施用是活性的，但在激发前24小时（或更长时间）以0.2%施用时不是活性的。动物模型：雄性注射Salin或BTX-B剂量：1μL（0.09%）/眼给药：滴眼液；每眼1μL（0.09%）；每天两次；4周结果：治疗后4周角膜荧光素染色评分改善。

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品

CAS号：91714-94-2

2-(2-氨基-3-(4-溴苯...

￥225.00

海关编码	2922509090

Material Safety Data Sheet

Section1. Identiﬁcation of the substance
Product Name: Bromfenac
Synonyms:

Section2. Hazards identiﬁcation
Harmful by inhalation, in contact with skin, and if swallowed.

Section3. Composition/information on ingredients.
Ingredient name:Bromfenac
CAS number:91714-94-2

Section4. First aid measures
Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
ﬂushing of the eyes by separating the eyelids with ﬁngers. If irritation persists, seek medical
attention.
Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section5. Fire ﬁghting measures
In the event of a ﬁre involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution:Wear approved mask/respirator
Hand precaution:Wear suitable gloves/gauntlets
Skin protection:Wear suitable protective clothing
Eye protection:Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section7. Handling and storage
Handling:This product should be handled only by, or under the close supervision of, those properly qualiﬁed
in the handling and use of potentially hazardous chemicals, who should take into account the ﬁre,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section9. Physical and chemical properties
Appearance:Not speciﬁed
Boiling point:No data
No data
Melting point:
Flash point:No data
Density:No data
Molecular formula:C15H12BrNO3
Molecular weight:334.2

Section10. Stability and reactivity
Conditions to avoid: Heat, ﬂames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section11. Toxicological information
No data.

Section12. Ecological information
No data.

Section13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section14. Transportation information
Non-harzardous for air and ground transportation.

Section15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

SECTION 16 - ADDITIONAL INFORMATION
N/A

[1]. Tetsuo Kida, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014 May 5;9(5):e96481.

[2]. Xiaobo Zhang, et al. Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification. Bioact Mater. 2021 Jul 23;9:343-357.

[3]. Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25(1-2): 77-85.

[4]. Kaevalin Lekhanont, et al. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007 Feb;23(1):27-34.